Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

ABSTRACT: Chimeric antigen receptor (CAR)-T cells have made great progress in hematological malignancies and optimization of CAR structure is a critical area of exploration. Limited research has evaluated humanized CD19-targeted CAR-T cells (hCART19) in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). We conducted a clinical trial to determine the safety of hCART19 for patients with R/R B-NHL. Successful infusion of hCART19 were achieved for 26 patients. Twenty-one (80.8%) patients had grade 1-2 cytokine release syndrome (CRS), with only 1 patient having grade 3 CRS. Besides, no immune effector cell-associated neurotoxicity (ICANS) was observed among all the patients. Twenty-one (80.8%) patients achieved an objective response, including 18 (69.2%) complete remission (CR) and 3 (11.5%)

SUBMITTER: Dong Y 

PROVIDER: S-EPMC12583143 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature